High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer
暂无分享,去创建一个
A. Haese* | G. Sauter | T. Schlomm | S. Steurer | T. Krech | C. Wittmer | R. Simon | W. Wilczak | S. Minner | M. Tsourlakis | M. Graefen | M. Kluth | C. Hube-Magg | J. Izbicki | C. Koop | P. Lebok | Meike Adam | N. Melling | L. Harutyunyan | Corinna Wittmer
[1] S. Kurtz,et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.
[2] J. Korbel,et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.
[3] E. Wieben,et al. The genomic landscape of small intestine neuroendocrine tumors. , 2013, The Journal of clinical investigation.
[4] G. Sauter,et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.
[5] V. Beneš,et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.
[6] S. Dedhar,et al. Integrin-Linked Kinase Regulates Interphase and Mitotic Microtubule Dynamics , 2013, PloS one.
[7] Yuzhuo Wang,et al. Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. , 2012, Carcinogenesis.
[8] C. Plass,et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.
[9] Bruce J Trock,et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.
[10] Tim Beißbarth,et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.
[11] A. Le Bivic,et al. Hook2 is involved in the morphogenesis of the primary cilium , 2011, Molecular biology of the cell.
[12] H. Schlüter,et al. ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.
[13] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[14] Hartwig Huland,et al. Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.
[15] K. Friedrich,et al. Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer. , 2010, Analytical and quantitative cytology and histology.
[16] L. Tsai,et al. Hook3 Interacts with PCM1 to Regulate Pericentriolar Material Assembly and the Timing of Neurogenesis , 2010, Neuron.
[17] F. Saad,et al. PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.
[18] C. Cooper,et al. ETS gene fusions in prostate cancer , 2009, Nature Reviews Urology.
[19] S. Gygi,et al. An FTS/Hook/p107(FHIP) complex interacts with and promotes endosomal clustering by the homotypic vacuolar protein sorting complex. , 2008, Molecular biology of the cell.
[20] K. Nielsen,et al. Is PTEN loss associated with clinical outcome measures in human prostate cancer? , 2008, British Journal of Cancer.
[21] E. Lundberg,et al. A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies* , 2008, Molecular & Cellular Proteomics.
[22] J. Köllermann,et al. Identifizierung und Validierung klinisch relevanter molekularer Veränderungen im Prostatakarzinom , 2008, Der Urologe.
[23] L. Foster,et al. Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization , 2008, The Journal of cell biology.
[24] T. Giordano,et al. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. , 2007, Endocrine-related cancer.
[25] H. Krämer,et al. Hook2 Localizes to the Centrosome, Binds Directly to Centriolin/CEP110 and Contributes to Centrosomal Function , 2007, Traffic.
[26] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[27] Viviane Poupon,et al. Mammalian late vacuole protein sorting orthologues participate in early endosomal fusion and interact with the cytoskeleton. , 2003, Molecular biology of the cell.
[28] Xinran Liu,et al. The Golgi-Associated Hook3 Protein Is a Member of a Novel Family of Microtubule-Binding Proteins , 2001, The Journal of cell biology.
[29] H. Krämer,et al. Genetic analysis of hook, a gene required for endocytic trafficking in drosophila. , 1999, Genetics.
[30] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[31] Rafael J. Yáñez-Muñoz,et al. Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. , 2011, American journal of cancer research.
[32] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[33] J. Köllermann,et al. [Identification and validation of clinically relevant molecular alterations in prostate cancer]. , 2008, Der Urologe. Ausg. A.
[34] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.